Kenichiro Yoshida

Title: Kenichiro Yoshida: Innovator in Cancer Treatment

Introduction

Kenichiro Yoshida is a prominent inventor based in Tsukuba, Japan. He has made significant contributions to the field of cancer treatment, particularly for patients with severe renal impairment. With a total of 4 patents to his name, Yoshida's work is paving the way for innovative therapeutic methods.

Latest Patents

Yoshida's latest patents focus on a method for treating cancer patients with severe renal impairment. This method involves a combination drug containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride. The treatment is designed for patients with a creatinine clearance of 15 mL/min or more and less than 30 mL/min. The drug is administered in a molar ratio of 1:0.5, with a dosage of 30 to 50 mg/m/day as FTD-equivalent, divided into two to four doses per day.

Career Highlights

Kenichiro Yoshida is currently employed at Taiho Pharmaceutical Company Limited, where he continues to develop innovative treatments for cancer. His work is characterized by a commitment to improving patient outcomes and addressing the unique challenges faced by those with renal impairment.

Collaborations

Yoshida collaborates with talented coworkers, including Lei Yu and Yun Wu, to advance research and development in cancer therapies. Their combined expertise contributes to the success of their projects and the potential for groundbreaking treatments.

Conclusion

Kenichiro Yoshida's contributions to cancer treatment highlight the importance of innovation in medicine. His patents and ongoing work at Taiho Pharmaceutical Company Limited demonstrate a dedication to improving the lives of patients with severe renal impairment.